TRADE MARKS ACT 1995
DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS
Re:Opposition by Neurim Pharmaceuticals (1991) Ltd to extension of protection under regulation 17A.33 of the Trade Marks Regulations 1995 (Cth) of trade mark number 1933662 (international registration number 1406500) (class 1) – B-CIRCADIN in the name of Clariant AG
Delegate: | Timothy Brown |
Representation: | Opponent: Jennifer McEwan & Jessica Murphy, Wrays Pty Ltd Holder: Griffith Hack Pty Ltd |
Decision: | 2021 ATMO 44 Trade Marks Regulations 1995 (Cth) – opposition to extension of protection to an international registration designating Australia under regulation 17A.33 – ss 42(b), 44, 58 and 60 – no grounds established – extension of protection allowed. |
Background
This is an opposition brought by Neurim Pharmaceuticals (1991) Ltd (‘Opponent’) to the extension of protection in Australia for the following International Registration Designating Australia:
Trade Mark: B-CIRCADIN (‘IRDA’)
Trade Mark Number: 1933662
IR Number: 1406500
Holder: Clariant AG (‘Holder’)
Filing date: 22 March 2018
Convention Priority Date: 19 January 2018 (‘Priority Date’)
Specification of Goods:
Class 1: Active chemical ingredients and chemical products for use in the cosmetic industry, excluding the pharmaceutical industry; active botanical ingredients and plant extracts for use in the cosmetic industry, excluding the pharmaceutical industry
The decision to accept the IRDA was notified in the Australian Official Journal of Trade Marks on 27 November 2018.
A notice of intention to oppose the extension of protection was filed by the Opponent on 29 January 2019. The statement of grounds and particulars (‘SGP’) was then filed on the 28 February 2019.
The Holder filed a notice of intention to defend on the 11 April 2019. Evidence in Support was filed by the Opponent on 8 July 2019. Evidence in Answer was filed by the Holder on 11 October 2019. Evidence in reply was not filed by the Opponent.
A hearing was scheduled for the 5 February 2021 and the parties were invited to make written submissions. Both parties advised that they would rely on written submissions. Consequently, the matter proceeded to hearing by way of written submission. The Opponent’s submissions were filed on the 25 January 2021. The Holder’s submissions were filed on 3 February 2021.
As the delegate of the Registrar, I will decide this matter with reference to the material filed during these proceedings.
Evidence
The Opponent
The Opponent filed Evidence in Support comprising of a declaration made by Professor Nava Zisapel on 7 July 2019 (‘Zisapel Declaration’) and Annexures 1 to 15.
The Zisapel Declaration explains that the Opponent is a pharmaceutical research and development company based in Switzerland with a focus on the treatment of age-related disorders.
The Opponent is the owner of the following trade mark registration in Australia:
Trade Mark Number: 743539
Trade Mark: CIRCADIN (‘Trade Mark Registration’)
Priority Date: 9 September 1997
Specification: Class 5 - Preparations and drugs for pharmaceutical use
The Opponent is also the owner of a number…
Keep reading for free
Create a free CaseChat account to read Neurim Pharmaceutical (1991) Ltd v Clariant AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2021] ATMO 44
- Decision Date
CaseChat Overview and Summary
The court was required to determine whether the grounds of opposition, based on sections 42(b), 44, 58, and 60 of the *Trade Marks Act 1995* (Cth), were established. Specifically, the court had to consider if the Holder's proposed trade mark was likely to deceive or cause confusion, if it was substantially identical or deceptively similar to the Opponent's registered mark, or if it was an improper use of a registered trade mark.
The court found that the Opponent had not established any of the nominated grounds of opposition. The Opponent's evidence detailed its use of CIRCADIN for pharmaceutical products, while the Holder's evidence explained its use of B-CIRCADIN for cosmetic ingredients sold through business-to-business channels. The court concluded that the differences in the marks and their respective goods and services, as well as the distinct marketing channels, meant there was no likelihood of deception or confusion. Consequently, the opposition was dismissed, and the extension of protection for the Holder's international registration was allowed. The Opponent was ordered to pay the costs of the Holder.
Orders
Orders of the court
Both parties have sought an award of costs. As the Opponent has not been successful in their opposition to the extension of protection of the IRDA, I award costs against the Opponent in accordance with Schedule 8 of the Trade Mark Regulations 1995 (Cth).
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
The Opponent filed Evidence in Support comprising of a declaration made by Professor Nava Zisapel on 7 July 2019 (‘Zisapel Declaration’) and Annexures 1 to 15. The Zisapel Declaration explains that the Opponent is a pharmaceutical research and development company based in Switzerland with a focus on the treatment of age-related disorders. The Opponent is the owner of the following trade mark registration in Australia:Trade Mark Number: 743539Trade Mark: CIRCADIN (‘Trade Mark Registration’)Priority Date: 9 September 1997Specification: Class 5 - Preparations and drugs for pharmaceutical use The Opponent is also the owner of a number of foreign registrations for CIRCADIN, including registrations in the United Kingdom, Europe, United States, Israel, South Africa, Thailand, Singapore, Mexico, China, Japan, and South Korea. Products bearing the Trade Mark Registration were first sold internationally in August 2007. In Australia, the products were first sold in March 2010 by the company Aspen Pharma Pty Ltd (‘Aspen’). Aspen sell and market goods bearing the Trade Mark Registration in Australia as the Opponent’s local representative. The Opponent outlines the use of the Trade Mark Registration in Australia as follows: The following Evidence in Answer was filed by the Holder: The Horikoshi Declaration explains that the Holder is a speciality chemicals company focusing on care chemicals, catalysis, natural resources, plastics, and coatings that sells its products as ingredients to, amongst others, manufacturers of consumer products. The company was formed in 1995 after previously being a part of the Swiss company Sandoz. Sandoz previously sold speciality chemicals and pharmaceuticals. In January 2017, the Holder began developing products in the nature of active ingredients for the cosmetic industry and specifically for skin and hair care products. One of these products was an active ingredient extracted from the medicinal plant lespedeza capitata, which the Holder called B-CIRCADIN. The name B-CIRCADIN was adopted to reflect the product’s impact on the human body’s circadian rhythm. The prefix ‘B’ was included as a reference to blue light. The Holder filed a trade mark application with the Swiss Intellectual Property Office on 19 January 2018, which was subsequently registered on 22 March 2018 under trade mark number 714424. This registration formed the basis for a number of applications for the extension of trade mark protection in other jurisdictions, including the United States, United Kingdom, European Union, India, South Korea, Russia and Mexico. The Holder sells products bearing the IRDA via business-to-business channels rather than directly to consumers. These channels include direct approach from the Holder’s sale representatives, as well as trade shows targeted at cosmetic manufacturers. The Sinclair Declaration provides information and evidence concerning trade shows referenced in the Horikoshi Declaration. The nominated grounds of opposition are sections 42(b), 44, 58, and 60 of the Trade Marks Act 1995 (Cth) (‘Act’).